Comparing two regimens of magnesium sulphate for treatment of eclampsia in pregnant wome
Phase 4
- Conditions
- Health Condition 1: null- Eclampsia during pregnancy and postpartum period
- Registration Number
- CTRI/2012/04/002594
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
All cases of eclampsia â?? antepartum, intrapartum, postpartum with following diagnostic criteria:
a)Hypertension where BP 140/90 mm Hg or more
b)Proteinuria (more than 0.3g/L or more than + 1)
c)Convulsion occurring at gestational age > 20 weeks, or within 48 h of delivery
Exclusion Criteria
Eclampsia with the following conditions will be excluded:
a.Renal failure
b.Deeply comatosed
c.Hypotensive patient
d.Clinical or imaging evidence suggestive of intracranial haemorrhage
e.Diagnosis is doubtful
f.Patients who had other causes of convulsions such as epilepsy, meningitis, trauma, and cerebral malaria etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The outcomes of two regimens are compared in terms of <br/ ><br>a)Rate of recurrent convulsions <br/ ><br>b)Maternal mortalityTimepoint: Till discharge
- Secondary Outcome Measures
Name Time Method <br/ ><br>1. Magnesium Sulphate â?? a)Total amount of magnesium sulphate received by each patient with or without maintenance dose <br/ ><br>b) Total no. of maintenance dose received <br/ ><br>c) Total no. of additional dose of magnesium sulphate received <br/ ><br>d) clinical evidence of magnesium toxicity such as absent patellar jerk, respiratory depression to be found <br/ ><br>2. Mode of delivery <br/ ><br> Normal delivery/ caesarean section/ forceps <br/ ><br>3. Maternal morbidity <br/ ><br>4. Perinatal mortality <br/ ><br>5.Neonatal morbidityTimepoint: Till discharge